Antioxidant stimulation as the adaptation mechanism in patients with metastatic urothelial cancers (MUC) treated with gemcitabine and cisplatin (GC).

Authors

Patrik Palacka

Patrik Palacka

2nd Oncology Department, School of Medicine, Comenius University and National Cancer Institute, Bratislava, Slovakia

Patrik Palacka , Jarmila Kucharska , Michal Mego , Jana Obertova , Jan Rajec , Daniela Svetlovska , Zuzana Sycova-Mila , Anna Mataseje , Jozef Mardiak , Anna Gvozdjakova

Organizations

2nd Oncology Department, School of Medicine, Comenius University and National Cancer Institute, Bratislava, Slovakia, Comenius University, Medical Faculty, Pharmacobiochemical Laboratory of Third Medical Department, Bratislava, Slovakia, 2nd Oncology Department, Comenius University, Medical School in Bratislava and National Cancer Institute, Bratislava, Slovakia, Department of Medical Oncology, School of Medicine, Comenius University; National Cancer Institute, Bratislava, Slovakia, 2nd Oncology Department, Comenius University, Medical School and National Cancer Institute, Bratislava, Slovakia, National Cancer Institute, Bratislava, Slovakia, Comenius University in Bratislava, Institute of Physiology, Faculty of Medicine, Bratislava, Slovakia

Research Funding

No funding sources reported

Background: The role of oxidative stress inpatients with MUC treated with GC is unknown. The objective of this ongoing study is to determinate plasma antioxidants, lipid peroxidation, and lipids in pts. with MUC before and after GC treatment, and to compare them with control. Methods: From May 2010 – January 2012, 42 MUC patients were enrolled into this study. The median of age was 65 years (range 44–81), median of metastasis sites was 2 (range 1–7). All patients were treated with gemcitabine 1000 mg/m2 i.v. days 1 and 8 with cisplatin 75 mg/m2 i.v. day 1, the new cycle of treatment started on day 22. Plasma samples were collected before and after 3 cycles of chemotherapy with GC. The control consisted of 22 subjects without cancer with age median 61 years (range 39–66). Results: In MUC patients, plasma γ-tocopherol before treatment were significantly lower (1.77±0.70 vs 2.13±0.70 μmol/L, P<0.04) and plasma TBARS higher vs control (5.76±1.32 vs 4.51±0.56 μmol/L, P<0.001). When compared baseline plasma levels to values after 3 cycles of GC, significant changes were noticed: γ-tocopherol (1.77±0.70 vs 2.29±1.14 μmol/L, P<0.04), α-tocopherol (24.23±5.14 vs 29.25±6.24 μmol/L, P<0.003), CoQ10-TOTAL (0.43±0.15 vs 0.56±0.16 μmol/L, P=0.003). TBARS concentrations were significantly decreased (5.76±1.32 vs 4.85±1.08 μmol/L, P=0.01). The concentrations of plasma lipids after GC were increased: Cholesterol (4.61±0.99 vs 5.47±1.21 mmol/L, P<0.004), TAG (1.30±0.65 vs 1.74±0.81 mmol/L, P<0.02), LDL cholesterol (2.94±0.73 vs 3.46±0.86 mmol/L, P<0.02), VLDL cholesterol (0.59±0.30 vs 0.81±0.37 mmol/L, P<0.02), and HDL cholesterol (1.08±0.39 vs 1.24±0.43 mmol/L, NS). Conclusions: GC in patients with MUC stimulated antioxidant defence system, increased plasma lipids, and decreased lipid peroxidation. The antioxidant stimulation might be one of the adaptation mechanisms that protect organism and might prevent or reduce chemotherapy side-effects. Acknowledgement: Study is supported by VEGA 1/0614/12 and Ministry of Health, Slovakia, grant 2007/29-UK-06.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2013 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancer, and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancer

Sub Track

Urothelial Carcinoma

Citation

J Clin Oncol 31, 2013 (suppl 6; abstr 281)

DOI

10.1200/jco.2013.31.6_suppl.281

Abstract #

281

Poster Bd #

G10

Abstract Disclosures